Study: Phosphate Binder Noncompliance Underreported

Share this content:

NATIONAL HARBOR, Md.—Dialysis patient underreporting of noncompliance with phosphate binder therapy may contribute to poor phosphorus control, investigators reported at the National Kidney Foundation 2012 Spring Clinical Meetings.

Nischala Dhanekula, MD, and collaborators at Unity Health System in Rochester, N.Y., interviewed 60 adult dialysis patients with uncontrolled phosphorus levels (mean levels of 5.5 mg/dL or above) using a questionnaire. They compared these patients with a control group of 40 dialysis patients with mean phosphorus levels below 5.5 mg/dL.

Results showed that 25.4% of the uncontrolled patients reported that they missed taking their binders on a daily basis, which was a significantly greater percentage than the 2.5% observed in the control group. However, pharmacy records indicated that 41.7% of the uncontrolled patients were not filling their prescriptions regularly, indicating that about 16% of this group underreported their noncompliance, the researchers stated.

In addition, the study showed that patient knowledge about high phosphorus diets did not differ significant between the groups. Interestingly, the investigators noted, the uncontrolled patients were better able to identify the health risks associated with high phosphorus.

Dr. Dhanekula's group concluded that drug dispensing information from pharmacies may play a role in controlling hyperphosphatemia.

You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters